We’ve been watching our web traffic grow month-to-month at a double-digit pace. In June, traffic at Endpoints News hit 313,439, exactly 10% higher than the month before, with 161,226 unique visitors to the site. And our subscriber list broke the 16,000 mark – heavily concentrated among biopharma executives — as we head straight to 20,000 this fall.
I like to say that Endpoints is the oldest new biopharma pub on the block. For those of you who have followed me over the past 15 years – including much of the 14 years before Arsalan Arif and I partnered on the launch on June 20, 2016 – it’s that track record and ability to swiftly add context to the news that makes this pub different from all of the rest. And as we grow the staff this summer, you can bet that we’ll be looking to continue to broaden our coverage base and geographic reach as we look to grow the audience and web traffic to 500,000-plus in the near future.
What I’m particularly happy about is that we accomplished this with a small team and exactly nothing to spend on a marketing campaign. All of our growth has been through word-of-mouth recommendations and our social media presence, with a big boost recently from Google News. When you’re boot-strapping a new, digital pub like this, you’ve got nothing extra for marketing. So we’re all extraordinarily grateful for your support and the steady stream of notes from readers.
This literally could never have happened without your help.
To help fund the second year of growth, Arsalan and I are prepping a subscriber campaign for Endpoints Insider that will get underway early next week. As we’ve already made clear, we are not going behind a paywall. The news will remain online and easily accessible. We are looking for readers who support the mission, or simply no longer wish to get emailed advertising, to subscribe to Endpoints for $200 a year.
No payment details required today
There’s also a $1,000/per year corporate rate for groups, no matter what size. That includes full reprint and republishing rights of our content for all legitimate business cases — perfect for PR agencies who want to send articles in full to clients, corporate intranets, trade show advertising, website posting, and more. Whether you are a multinational corporation or a small shop, the enterprise rate is the same.
We’ve had a strong response from our first word on this new campaign. And you can add your name to our preregistration list here. (You won’t be billed today or asked to provide payment details.)
It’s been a great start. And the rest of 2017 and all of 2018 are going to be gangbusters. I guarantee you won’t want to miss it. — John Carroll
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.Free Subscription